ClinicalTrials.gg
CompletedNCT05083182PSUMMIT-JrUpdated Jul 31, 2026

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

A Phase 3 interventional study of Ustekinumab and Guselkumab in Arthritis, Juvenile, sponsored by Janssen Research & Development, LLC. Completed at 50 sites in 10 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Arthritis, Juvenile by Johnson & Johnson — 1 open to participants now, 1 under way, 1 of them phase 3. Arthritis, Juvenile · Johnson & Johnson.

Started
2022
with 1 other
Phase 3
5 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Arthritis, Juvenile by Johnson & Johnson, this one is one of 2 that started in 2022, is one of 5 in phase 3, and was the 8th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).

03

Conditions studied

  • Arthritis, Juvenile

Browse trials for

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of juvenile psoriatic arthritis (jPsA) by Vancouver criteria with exclusion of enthesitis-related arthritis (ERA). Diagnosis made >=3 months (that is, 90 days) prior to screening
  • Active disease in at least greater than or equal to (>=) 3 joints at screening and at week 0 (defined as swelling or loss of motion with pain and/or tenderness. Swelling alone meets the criteria for an active arthritic joint. In the absence of swelling, loss of motion with pain or tenderness or both pain and tenderness meet the criteria for an active arthritic joint
  • Have active disease despite previous non-biologic disease modifying anti-rheumatic drug (DMARD) and/or non-steroidal anti-inflammatory drug (NSAID) therapy: Non-biologic DMARD therapy is defined as taking a non-biologic DMARD for at least 12 weeks or evidence of intolerance; NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of intolerance
  • Concurrent use of methotrexate, sulfasalazine, leflunomide, oral or NSAIDs is permitted but must be on stable dose
  • Participants must be up to date with all immunizations in agreement with current local immunization guidelines for patients
  • Prior use of anti-TNFα agents, IL-17 inhibitors and other biologics (except non-responders to IL-23 inhibitors) and JAK inhibitors are permitted with sufficient

Exclusion criteria

Exclusion Criteria:

  • Participants with enthesitis-related arthritis (ERA)
  • Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis prior to screening
  • Have a history of, or ongoing, chronic or recurrent infectious disease
  • Has evidence of herpes zoster infection within 8 weeks prior to Week 0
  • Have a known history of infection or test positive at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1: Ustekinumab

    Participants will receive a weight-based dose of ustekinumab subcutaneously (SC) at Week 0, Week 4 and then every 12 weeks up to Week 52. Cohort 1 is closed for further enrollment.

    Drug: Ustekinumab

  • Experimental
    Cohort 2: Guselkumab

    The dose of guselkumab will be based on the participant's weight. Participants will receive guselkumab SC at Weeks 0 and 4 followed by either every 4 weeks (Q4W) (with historical radiographic evidence of joint damage) or every 8 weeks (Q8W) (without historical evidence of joint damage) dosing with the last dose at Week 52. Participants at high risk of joint damage can also be considered for Q4W dosing per investigator.

    Drug: Guselkumab

Interventions

  • Ustekinumab will be administered as subcutaneous injection.

    Also known as: CNTO1275, STELARA

  • Guselkumab will be administered as subcutaneous injection.

    Also known as: CNTO1959, TREMFYA

06

What researchers measure

Primary outcomes

  1. Cohort 1: Steady-state Trough Serum Concentration of Ustekinumab at Week 28 by Baseline Age Groups

    Steady-state trough serum concentration of ustekinumab at Week 28 by baseline age groups will be reported.

    Time frame: Week 28

  2. Cohort 2: Steady-state Trough Serum Concentration of Guselkumab at Week 28 by Baseline Age Groups

    Steady-state trough serum concentration of guselkumab at Week 28 by baseline age groups will be reported.

    Time frame: Week 28

  3. Cohort 1: Area Under the Curve at Steady-state (AUCss) Over a 12-Week Dosing Interval of Ustekinumab at Week 28 by Baseline Age Groups

    AUCss is defined as area under the curve at steady-state over a 12-week dosing interval of ustekinumab at Week 28 by baseline age groups.

    Time frame: Week 28

  4. Cohort 2: AUCss Over a Dosing Interval (4 or 8 Weeks) of Guselkumab at Week 28 by Baseline Age Groups

    AUCss is defined as area under the curve at steady-state over a dosing interval (4 or 8 weeks) of guselkumab at Week 28 by baseline age groups.

    Time frame: Week 28

  5. Cohort 1: Percentage of Participants with Juvenile Psoriatic Arthritis (jPsA) Achieving American College of Rheumatology (ACR) Pediatric 30 Response at Week 24

    Percentage of Participants with jPsA achieving ACR pediatric 30 response at Week 24 will be reported. The ACR pediatric 30 response criteria is defined as a 30 percent (%) improvement (that is, a decrease in score) from baseline in greater than or equal to (\>=) 3 of the following 6 components, with worsening of \>=30% in no more than 1 of the following components: physician global assessment (PGA) of disease activity, patient/participant assessment of overall well-being, number of active joints (defined as swelling or loss of motion with pain and/or tenderness), number of joints with limited range of motion, physician function by childhood health assessment questionnaire (CHAQ) and C-reactive protein (CRP).

    Time frame: Week 24

  6. Cohort 2: Percentage of Participants with jPsA Achieving ACR Pediatric 30 Response at Week 24

    Percentage of Participants with jPsA achieving ACR pediatric 30 response at Week 24 will be reported. The ACR pediatric 30 response criteria is defined as a 30% improvement (that is, a decrease in score) from baseline in \>=3 of the following 6 components, with worsening of \>=30% in no more than 1 of the following components: PGA of disease activity, patient/participant assessment of overall well-being, number of active joints (defined as swelling or loss of motion with pain and/or tenderness), number of joints with limited range of motion, physician function by CHAQ and CRP.

    Time frame: Week 24

Secondary outcomes

  1. Cohorts 1: Steady-state Trough Serum Concentration of Ustekinumab at Week 52 by Baseline Age Groups

    Steady-state trough serum concentration of ustekinumab at Week 52 by baseline age groups will be reported.

    Time frame: Week 52

  2. Cohorts 2: Steady-state Trough Serum Concentration of Guselkumabat at Week 52 by Baseline Age Groups

    Steady-state trough serum concentration of guselkumab at Week 52 by baseline age groups will be reported.

    Time frame: Week 52

  3. Cohort 1: AUCss Over a 12-Week Dosing Interval of Ustekinumab at Week 52 by Baseline Age Groups

    AUCss is defined as area under the curve at steady-state over a 12-week dosing interval of ustekinumab at Week 52 by baseline age groups.

    Time frame: Week 52

  4. Cohort 2: AUCss Over a Dosing Interval (4 or 8 Weeks) of Guselkumab at Week 52 by Baseline Age Groups

    AUCss is defined as area under the curve at steady-state over a dosing interval (4 or 8 weeks) of guselkumab at Week 52 by baseline age groups.

    Time frame: Week 52

  5. Cohorts 1 and 2: Percentage of Participants Achieving ACR Pediatric 30 Response at Weeks 4, 8, 12, 16, and 52

    The ACR pediatric 30 response criteria is defined as a 30% improvement (that is, a decrease in score) from baseline in \>=3 of the following 6 components, with worsening of \>=30% in no more than 1 of the following components: PGA of disease activity, patient/participant assessment of overall well-being, number of active joints (defined as swelling or loss of motion with pain and/or tenderness), number of joints with limited range of motion, physician function by CHAQ and CRP.

    Time frame: Weeks 4, 8, 12, 16 and 52

  6. Cohorts 1 and 2: Percentage of Participants Achieving ACR Pediatric 50 and 70 Responses at Weeks 4, 8, 12, 16, 24, and 52

    The ACR pediatric 50 and 70 responses are defined as a 50% improvement or 70% improvement (that is, a decrease in score) from baseline in \>=3 of the following 6 components, with worsening of \>=30% in no more than 1 of the following components: 1 of the following components: PGA of disease activity, patient/participant assessment of overall well-being, number of active joints (defined as swelling or loss of motion with pain and/or tenderness), number of joints with limited range of motion, physician function by CHAQ and CRP.

    Time frame: Weeks 4, 8, 12, 16, 24, and 52

  7. Cohorts 1 and 2: Time to Response Measured as Time to Achieving ACR Pediatric 30

    Time to response measured as time to achieving ACR pediatric 30 will be reported.

    Time frame: Baseline, up to Week 24

  8. Cohorts 1 and 2: Change from Baseline in Clinical Juvenile Arthritis Disease Activity Score (cJADAS) 10 at Weeks 4, 8, 12, 16, 24, and 52

    Change from baseline in cJADAS 10 at Weeks 4, 8, 12, 16, 24, and 52 will be reported. The cJADAS is calculated as the sum of the scores of its 3 components: (1) physician global rating of overall disease activity, measured on a 10-cm horizontal visual analog scale; (2) parent/child ratings of well-being, assessed on a 10 cm horizontal line VAS; (3) number of active joints, assessed in 10 joints, for a total score ranging from 0 to 30 where 0=no activity and 30=maximum activity.

    Time frame: Baseline, up to Weeks 4, 8, 12, 16, 24, and 52

  9. Cohorts 1 and 2: Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 10, 27 and 71 at Weeks 4, 8, 12, 16, 24, and 52

    Change from baseline in JADAS 10, 27 and 71 at Weeks 4, 8, 12, 16, 24, and 52 will be reported. The JADAS is calculated as the sum of the scores of its 4 components: (1) physician global rating of overall disease activity, measured on a 10-cm horizontal visual analog scale; (2) parent/child ratings of well-being, assessed on a 10 cm horizontal line VAS; (3) number of active joints, assessed in 71, 27, or 10 joints (for JADAS 71, JADAS 27, and JADAS 10, respectively); (4) CRP (truncated to 0-10 mg/dL).

    Time frame: Baseline, up to Weeks 4, 8, 12, 16, 24, and 52

  10. Cohorts 1 and 2: Change from Baseline in Psoriasis Area Severity Index (PASI) Score at Week 24

    Change from baseline in PASI score at Week 24 among the participants with greater than or equal to (\>=) 3% body surface area (BSA) psoriatic involvement and a PGA psoriasis score of \>=2 (mild) at baseline will be reported. The PASI includes assessments of 4 areas of the body: the head and neck, the arms, the trunk, and the legs. The percentage of skin in each area affected by psoriasis is given a numeric score representing the proportion involved. The severity of the 3 plaque signs of erythema, thickness/induration, and desquamation/scaling, is assessed on a 5-point scale. The total PASI score is from 0-72, where 0=no disease and 72=more disease.

    Time frame: Baseline and Week 24

  11. Cohorts 1 and 2: Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to Week 68

  12. Cohorts 1 and 2: Percentage of Participants with Serious Adverse Events (SAEs)

    A SAE is any untoward medical occurrence that at any dose results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

    Time frame: Up to Week 68

  13. Cohorts 1 and 2: Percentage of Participants with Reasonably Related AEs

    Percentage of participants with reasonably related AEs (including injection-site reactions and infections) will be reported.

    Time frame: Up to Week 68

  14. Cohorts 1: Number of Participants with Antibodies to Ustekinumab

    Number of participants with antibodies to ustekinumab (including peak titers) will be reported.

    Time frame: Weeks 52 and 68

  15. Cohorts 2 : Number of Participants with Antibodies to Guselkumab

    Number of participants with antibodies to guselkumab (including peak titers) will be reported.

    Time frame: Weeks 52 and 68

07

Study locations

50 sites
  • Childrens Hospital Los Angeles
    Los Angeles, California 90027, United States
  • UCLA
    Los Angeles, California 90095-3075, United States
  • Harvard Medical School - Boston Children's Hospital
    Boston, Massachusetts 02215-5450, United States
  • Northwell Health
    New York, New York 11040, United States
  • Montefiore Medical Center
    The Bronx, New York 10467-2403, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Legacy Emanuel Medical Center
    Portland, Oregon 97227, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • STAT Research S A
    Ciudad Autonoma Buenos Aires, C1013AAAB, Argentina
  • Hospital de Ninos de Cordoba
    Córdoba, 5000, Argentina
  • Instituto Medico Platense
    La Plata, B1900, Argentina
  • Instituto Caici
    Rosario, S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucumán, T4000AXL, Argentina
  • Aarhus Universitetshospital
    Aarhus, 8200, Denmark
  • Odense Universitets Hospital
    Odense, 5000, Denmark
  • CHU de Caen
    Caen, 14033, France
  • Hopital de Bicetre
    Le Kremlin-Bicêtre, 94270, France
  • Hopital Nord Marseille
    Marseille, 13015, France
  • CHU de Toulouse Hopital des Enfants
    Toulouse, 31059, France
  • Hôpital D'Enfants
    Vandœuvre-lès-Nancy, 54511, France
  • Charite Universitatsmedizin Berlin Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Schon Klinik Hamburg Eilbek
    Hamburg, 22081, Germany
  • Asklepios Klinik Sankt Augustin
    Sankt Augustin, 53757, Germany
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
    Brescia, 25100, Italy
  • Istituto Giannina Gaslini
    Genova, 16147, Italy
  • Centro Specialistico Ortopedico Traumatologico Gaetano Pini CTO
    Milan, 20122, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesu
    Roma, 00165, Italy
  • CSK, Uniwersyteckie Centrum Pediatrii im.M.Konopnickiej
    Lodz, 91-738, Poland
  • Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu Sp z o o
    Sosnowiec, 41 200, Poland
  • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
    Warsaw, 02 637, Poland
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp. de La Santa Creu I Sant Pau
    Barcelona, 8041, Spain
  • Hosp Reina Sofia
    Córdoba, 14004, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • Hosp. Infanta Luisa
    Seville, 41010, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
  • Hacettepe Universitesi Hastanesi
    Ankara, 6230, Turkey (Türkiye)
  • Istanbul University Cerrahpasa Medical Faculty
    Istanbul, 34098, Turkey (Türkiye)
  • Umraniye Training and Research Hospital
    Istanbul, 34766, Turkey (Türkiye)
  • Kocaeli University Medical Faculty
    Kocaeli, 41380, Turkey (Türkiye)
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, NG7 2UH, United Kingdom
  • Sheffield Children's Hospital
    Sheffield, S10 2TH, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
  • Haywood Hospital
    Staffordshire, ST6 7AG, United Kingdom
  • Royal Stoke University Hospital
    Stoke-on-Trent, ST4 6QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2026, 40 months.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 19, 2021
StartActual
Aug 30, 2022
Primary completionActual
Jan 12, 2026
CompletionActual
Jun 23, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05083182
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Aug 30, 2022
Primary completion
Jan 12, 2026
Completion
Jun 23, 2026
Last update
Jul 31, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ustekinumab · Guselkumab

Start the discussion